Locations
South San Francisco, CA, USA · United States · North America
industry
Biotechnology · DeepTech · Health
Size
51-200 employees
Stage
Other
founded in
2016
Senti Bio is a clinical-stage biotechnology company focused on developing innovative cancer therapeutics using synthetic biology and proprietary Gene Circuits. Their approach involves reprogramming cells to enhance specificity in targeting cancer cells while sparing healthy ones. The company is advancing off-the-shelf CAR-NK cell therapy programs, with their lead product candidate SENTI-202 currently in clinical trials for acute myeloid leukemia (AML). Senti Bio also has partnered programs targeting hepatocellular carcinoma (HCC) and gene therapies for tissue-directed targets, positioning them as a key player in the oncology therapeutics market.
Something looks off?On-site & Remote